Obiettivo
UroSense is a focussed research programme to generate new concepts from knowledge creation to knowledge transfer between innovative academic and dedicated industry partners utilising a systematic intersectoral secondment programme. The programme brings leading edge academic European LifeScience capacities of Diabetes research at Dublin City University, Ireland, together with the high-profile protein research center of University of Luxembourg to establish innovative biomarker utilisation. The nano-biotechnologies developed with established life science applications of Tethis S.p.A of Milano, Italy will be the SME partner to translate findings to microfluidic applications while GE Medical System of Sweden will integrate results to the recently established, robust molecular imaging technologies leading to novel diagnostics for the benefit of the diabetes patient. The Chinese partner is a leading biotech company in Guangzhou who will provide not only validation of results but also to develop access to the fastest growing global healthcare market benefiting both academic and industrial partners. All European partners are unequivocally in the leading edge in their own sectors sharing the vision of true impacts achieved with a new collaborative working model including efficient knowledge transfer and a shared clear scientific focus. Our consortium is particularly well balanced, focussed and well resourced to cover the value chain from discovery research to applications utilising novel intersectoral collaborations to expedite the utilisation process.
Campo scientifico
Not validated
Not validated
Argomento(i)
Invito a presentare proposte
FP7-PEOPLE-2011-IAPP
Vedi altri progetti per questo bando
Meccanismo di finanziamento
MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)Coordinatore
9 Dublin
Irlanda